Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine with Steroids for First Line GI GVHD
NCT06598332Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine, sponsored by Baylor College of Medicine. Primary endpoints: Feasibility rate at 30 days and Treatment-related adverse event (tAE) rate at 30 days. Planned start Aug 2025; status: withdrawn.
02
Drugs
azacitidine
Beyond the preview
Go deeper on NCT06598332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598332.